Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY.

J Am Heart Assoc. 2014 Apr 14;3(2):e000849. doi: 10.1161/JAHA.114.000849.

2.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

3.
4.

Effect of spironolactone on patients with atrial fibrillation and structural heart disease.

Williams RS, deLemos JA, Dimas V, Reisch J, Hill JA, Naseem RH.

Clin Cardiol. 2011 Jul;34(7):415-9. doi: 10.1002/clc.20914. Epub 2011 Jun 14.

5.

The GoodNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial: a community-based participatory research (CBPR) trial with African-American church congregations for reducing cardiovascular disease risk factors--recruitment, measurement, and randomization.

DeHaven MJ, Ramos-Roman MA, Gimpel N, Carson J, DeLemos J, Pickens S, Simmons C, Powell-Wiley T, Banks-Richard K, Shuval K, Duvahl J, Tong L, Hsieh N, Lee JJ.

Contemp Clin Trials. 2011 Sep;32(5):630-40. doi: 10.1016/j.cct.2011.05.017. Epub 2011 Jun 2. Erratum in: Contemp Clin Trials. 2012 Nov;33(6):1321. Duval, Julie [corrected to Duvahl, Julie].

6.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M.

N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.

7.

Development of risk maps to minimize uranium exposures in the Navajo Churchrock mining district.

deLemos JL, Brugge D, Cajero M, Downs M, Durant JL, George CM, Henio-Adeky S, Nez T, Manning T, Rock T, Seschillie B, Shuey C, Lewis J.

Environ Health. 2009 Jul 9;8:29. doi: 10.1186/1476-069X-8-29.

8.

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.

Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26.

9.

Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit.

Cannon CP; STRIVE Scientific Committee.

Crit Pathw Cardiol. 2008 Dec;7(4):223-31. doi: 10.1097/HPC.0b013e31818b0c5c. Review.

PMID:
19050418
10.

Rapid dissolution of soluble uranyl phases in arid, mine-impacted catchments near Church Rock, NM.

deLemos JL, Bostick BC, Quicksall AN, Landis JD, George CC, Slagowski NL, Rock T, Brugge D, Lewis J, Durant JL.

Environ Sci Technol. 2008 Jun 1;42(11):3951-7.

11.

Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit.

Cannon CP; STRIVE Scientific Committee.

Crit Pathw Cardiol. 2008 Mar;7(1):43-81. doi: 10.1097/HPC.0b013e3181642955. Review.

PMID:
18458666
12.

Treatment delay in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a key process analysis of patient and program factors.

Parikh SV, Jacobi JA, Chu E, Addo TA, Warner JJ, Delaney KA, McGuire DK, deLemos JA, Cigarroa JE, Murphy SA, Keeley EC.

Am Heart J. 2008 Feb;155(2):290-7. doi: 10.1016/j.ahj.2007.10.021. Epub 2007 Dec 19.

PMID:
18215599
13.

The Sequoyah corporation fuels release and the Church Rock spill: unpublicized nuclear releases in American Indian communities.

Brugge D, deLemos JL, Bui C.

Am J Public Health. 2007 Sep;97(9):1595-600. Epub 2007 Jul 31.

14.

Racial disparity in clinical outcomes following primary percutaneous coronary intervention for ST elevation myocardial infarction: influence of process of care.

Jacobi JA, Parikh SV, McGuire DK, Delemos JA, Murphy SA, Keeley EC.

J Interv Cardiol. 2007 Jun;20(3):182-7.

PMID:
17524109
15.

Lessons from the Navajo: assistance with environmental data collection ensures cultural humility and data relevance.

DeLemos J, Rock T, Brugge D, Slagowski N, Manning T, Lewis J.

Prog Community Health Partnersh. 2007 Winter;1(4):321-6. doi: 10.1353/cpr.2007.0039.

16.

Landfill-stimulated iron reduction and arsenic release at the Coakley Superfund Site (NH).

deLemos JL, Bostick BC, Renshaw CE, Stürup S, Feng X.

Environ Sci Technol. 2006 Jan 1;40(1):67-73.

PMID:
16433334
17.

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators.

N Engl J Med. 2003 Nov 13;349(20):1893-906. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

18.

Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.

Morrow DA, Antman EM, Sayah A, Schuhwerk KC, Giugliano RP, deLemos JA, Waller M, Cohen SA, Rosenberg DG, Cutler SS, McCabe CH, Walls RM, Braunwald E.

J Am Coll Cardiol. 2002 Jul 3;40(1):71-7.

19.

Rescue ventilation with high frequency oscillation in premature baboons with hyaline membrane disease.

deLemos RA, Coalson JJ, deLemos JA, King RJ, Clark RH, Gerstmann DR.

Pediatr Pulmonol. 1992 Jan;12(1):29-36.

PMID:
1579373
20.

Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease.

deLemos RA, Roberts RJ, Coalson JJ, deLemos JA, Null DM Jr, Gerstmann DR.

Am J Dis Child. 1990 Aug;144(8):915-9.

PMID:
2378340
Items per page

Supplemental Content

Loading ...
Write to the Help Desk